Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01698905 · ClinicalTrials.gov registry record · Phase 2
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 163
- Enrollment target
NCT01698905 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 163 participants.
The verdict
NCT01698905, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 163 participants
- Enrollment target
Study Summary
A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients. Patients who started treatment with imatinib (Gleevec) when they were first diagnosed with CML, then switched to nilotinib (Tasigna) for at least 2 years with the combined time on imatinib (Gleevec) and nilotinib (Tasigna) for at least 3 years and have very small amount of leukemia cells remaining after the nilotinib (Tasigna) treatment will qualify for the study.
Interventions
- DRUG nilotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2012-12-20 |
| Est. Completion | 2025-01-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01698905
The ClinicalTrials.gov registry entry for NCT01698905 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nilotinib is the first listed.
NCT01698905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01698905 about?
NCT01698905 is a clinical study titled "Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)". A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients. Patients who started treatment with imatinib (Gleevec) when they were first diagnosed with CML, then switched to nilotinib (Tasigna) for at least 2 years with the comb...
What is the current status of trial NCT01698905?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2012-12-20. Estimated completion is 2025-01-29.
What interventions are being tested in trial NCT01698905?
The interventions under investigation include: nilotinib (DRUG).
Who is sponsoring clinical trial NCT01698905?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.